<bill session="117" type="h" number="4385" updated="2022-12-31T05:07:24Z">
  <state datetime="2021-07-09">REFERRED</state>
  <status>
    <introduced datetime="2021-07-09"/>
  </status>
  <introduced datetime="2021-07-09"/>
  <titles>
    <title type="official" as="introduced">To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost sharing for oral anticancer drugs on terms no less favorable than the cost sharing provided for anticancer medications administered by a health care provider.</title>
    <title type="display">Cancer Drug Parity Act of 2021</title>
    <title type="short" as="introduced">Cancer Drug Parity Act of 2021</title>
  </titles>
  <sponsor bioguide_id="H001038"/>
  <cosponsors>
    <cosponsor bioguide_id="A000371" joined="2022-09-28"/>
    <cosponsor bioguide_id="A000376" joined="2022-02-08"/>
    <cosponsor bioguide_id="B001300" joined="2022-07-29"/>
    <cosponsor bioguide_id="B001257" joined="2021-07-09"/>
    <cosponsor bioguide_id="B000574" joined="2021-11-18"/>
    <cosponsor bioguide_id="B001278" joined="2021-11-18"/>
    <cosponsor bioguide_id="B001295" joined="2022-07-13"/>
    <cosponsor bioguide_id="B001285" joined="2021-11-18"/>
    <cosponsor bioguide_id="B001248" joined="2022-09-21"/>
    <cosponsor bioguide_id="C001055" joined="2021-09-10"/>
    <cosponsor bioguide_id="C001066" joined="2022-09-28"/>
    <cosponsor bioguide_id="C001067" joined="2021-10-22"/>
    <cosponsor bioguide_id="C001061" joined="2022-09-21"/>
    <cosponsor bioguide_id="C001078" joined="2022-01-11"/>
    <cosponsor bioguide_id="D000619" joined="2022-02-01"/>
    <cosponsor bioguide_id="E000296" joined="2022-11-14"/>
    <cosponsor bioguide_id="F000466" joined="2022-02-01"/>
    <cosponsor bioguide_id="G000576" joined="2021-07-09"/>
    <cosponsor bioguide_id="G000558" joined="2021-07-09"/>
    <cosponsor bioguide_id="K000382" joined="2022-10-07"/>
    <cosponsor bioguide_id="L000579" joined="2022-11-14"/>
    <cosponsor bioguide_id="M001203" joined="2022-10-28"/>
    <cosponsor bioguide_id="M000087" joined="2021-11-18"/>
    <cosponsor bioguide_id="M001163" joined="2021-07-09"/>
    <cosponsor bioguide_id="M001208" joined="2021-10-20"/>
    <cosponsor bioguide_id="M001206" joined="2021-07-09"/>
    <cosponsor bioguide_id="N000179" joined="2022-09-21"/>
    <cosponsor bioguide_id="P000613" joined="2021-10-28"/>
    <cosponsor bioguide_id="P000597" joined="2022-02-01"/>
    <cosponsor bioguide_id="R000606" joined="2022-11-07"/>
    <cosponsor bioguide_id="S001201" joined="2021-11-18"/>
    <cosponsor bioguide_id="T000483" joined="2021-12-07"/>
    <cosponsor bioguide_id="W000826" joined="2021-10-05"/>
    <cosponsor bioguide_id="W000804" joined="2022-02-18"/>
    <cosponsor bioguide_id="Y000062" joined="2022-02-01"/>
    <cosponsor bioguide_id="Y000033" joined="2022-01-11"/>
  </cosponsors>
  <actions>
    <action datetime="2021-07-09">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-07-09" state="REFERRED">
      <text>Referred to the House Committee on Education and Labor.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSED" name="House Education and the Workforce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="3080" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-02-10T18:17:45Z" status="Introduced in House">Cancer Drug Parity Act of 2021

This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, plans may not,&#160;with respect to&#160;anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.</summary>
</bill>
